Shanghai Fosun Subsidiary Launches Phase III Clinical Trial for Luvometinib in China

Reuters
07-09
<a href="https://laohu8.com/S/SFOSF">Shanghai Fosun</a> Subsidiary Launches Phase III Clinical Trial for Luvometinib in China

Shanghai Fosun Pharmaceutical Industrial Development Company Limited, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd., has initiated a Phase III clinical trial for Luvometinib Tablets, branded as 復邁寧®. The trial focuses on treating children with low-grade glioma in China, excluding Hong Kong, Macau, and Taiwan. The drug is an innovative small molecule chemical developed internally by the company and its subsidiaries. This development marks a significant step in advancing treatments for pediatric gliomas, highlighting Fosun Pharma's commitment to pioneering healthcare solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief on July 09, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10